Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Opioid-induced Constipation Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Opioid-induced Constipation Market Status and Forecast (2016-2027)
      • 1.3.2 Global Opioid-induced Constipation Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Opioid-induced Constipation Supply by Company

    • 2.1 Global Opioid-induced Constipation Sales Value by Company
    • 2.2 Opioid-induced Constipation Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Opioid-induced Constipation Market Status by Category

    • 3.1 Opioid-induced Constipation Category Introduction
      • 3.1.1 Solid
      • 3.1.2 Liquid
    • 3.2 Global Opioid-induced Constipation Market by Category
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Opioid-induced Constipation Market Status by End User/Segment

    • 4.1 Opioid-induced Constipation Segment by End User/Segment
      • 4.1.1 Drugstore
      • 4.1.2 Hospital
      • 4.1.3 Others
    • 4.2 Global Opioid-induced Constipation Market by End User/Segment
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Opioid-induced Constipation Market Status by Region

    • 5.1 Global Opioid-induced Constipation Market by Region
    • 5.2 North America Opioid-induced Constipation Market Status
    • 5.3 Europe Opioid-induced Constipation Market Status
    • 5.4 Asia Pacific Opioid-induced Constipation Market Status
    • 5.5 Central & South America Opioid-induced Constipation Market Status
    • 5.6 Middle East & Africa Opioid-induced Constipation Market Status

    6 North America Opioid-induced Constipation Market Status

    • 6.1 North America Opioid-induced Constipation Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Opioid-induced Constipation Market Status

    • 7.1 Europe Opioid-induced Constipation Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Opioid-induced Constipation Market Status

    • 8.1 Asia Pacific Opioid-induced Constipation Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Opioid-induced Constipation Market Status

    • 9.1 Central & South America Opioid-induced Constipation Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Opioid-induced Constipation Market Status

    • 10.1 Middle East & Africa Opioid-induced Constipation Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Opioid-induced Constipation Market Forecast by Category and by End User/Segment

    • 12.1 Global Opioid-induced Constipation Sales Value Forecast (2022-2027)
    • 12.2 Global Opioid-induced Constipation Forecast by Category
    • 12.3 Global Opioid-induced Constipation Forecast by End User/Segment

    13 Global Opioid-induced Constipation Market Forecast by Region/Country

    • 13.1 Global Opioid-induced Constipation Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Theravance
      • 14.1.1 Company Information
      • 14.1.2 Opioid-induced Constipation Product Introduction
      • 14.1.3 Theravance Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Takeda Pharmaceutical
      • 14.2.1 Company Information
      • 14.2.2 Opioid-induced Constipation Product Introduction
      • 14.2.3 Takeda Pharmaceutical Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Synergy Pharmaceuticals
      • 14.3.1 Company Information
      • 14.3.2 Opioid-induced Constipation Product Introduction
      • 14.3.3 Synergy Pharmaceuticals Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Sucampo
      • 14.4.1 Company Information
      • 14.4.2 Opioid-induced Constipation Product Introduction
      • 14.4.3 Sucampo Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 SLA Pharma
      • 14.5.1 Company Information
      • 14.5.2 Opioid-induced Constipation Product Introduction
      • 14.5.3 SLA Pharma Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Shionogi
      • 14.6.1 Company Information
      • 14.6.2 Opioid-induced Constipation Product Introduction
      • 14.6.3 Shionogi Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Progenics Pharmaceuticals
      • 14.7.1 Company Information
      • 14.7.2 Opioid-induced Constipation Product Introduction
      • 14.7.3 Progenics Pharmaceuticals Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Pfizer
      • 14.8.1 Company Information
      • 14.8.2 Opioid-induced Constipation Product Introduction
      • 14.8.3 Pfizer Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Nektar Therapeutics
      • 14.9.1 Company Information
      • 14.9.2 Opioid-induced Constipation Product Introduction
      • 14.9.3 Nektar Therapeutics Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Mundipharma
      • 14.10.1 Company Information
      • 14.10.2 Opioid-induced Constipation Product Introduction
      • 14.10.3 Mundipharma Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Merck
    • 14.12 Johnson and Johnson
    • 14.13 Ironwood Pharmaceuticals
    • 14.14 GlaxoSmithKline
    • 14.15 Daiichi Sankyo
    • 14.16 Daewoong
    • 14.17 Cosmo Pharmaceuticals
    • 14.18 C.B. Fleet
    • 14.19 Boehringer Ingelheim
    • 14.20 Bayer
    • 14.21 Bausch Health
    • 14.22 AstraZeneca
    • 14.23 Abbott

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Opioid-induced Constipation market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Opioid-induced Constipation market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Solid
      Liquid

      Segmented by End User/Segment
      Drugstore
      Hospital
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Theravance
      Takeda Pharmaceutical
      Synergy Pharmaceuticals
      Sucampo
      SLA Pharma
      Shionogi
      Progenics Pharmaceuticals
      Pfizer
      Nektar Therapeutics
      Mundipharma
      Merck
      Johnson and Johnson
      Ironwood Pharmaceuticals
      GlaxoSmithKline
      Daiichi Sankyo
      Daewoong
      Cosmo Pharmaceuticals
      C.B. Fleet
      Boehringer Ingelheim
      Bayer
      Bausch Health
      AstraZeneca
      Abbott
      Buy now